References
- Pettifor AE, Rees HV, Kleinschmidt I et al. Young people’s sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. AIDS 19(14), 1525–1534 (2005).
- Shisana O, Rehle T, Simbayi LC et al. South African National HIV Prevalence, Incidence, Behaviour and Communication Survey 2008: A Turning tide Among Teenagers? HSRC Press, Cape Town, South Africa (2009).
- Stone A, Harrison PF. Microbicides – Ways Forward. Alliance for Microbicide Development, Silver Spring, MD, USA (2010).
- Stein ZA. HIV prevention: the need for methods women can use. Am. J. Public Health 80(4), 460–462 (1990).
- Richardson BA, Lavreys L, Martin HL Jr et al. Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex. Transm. Dis. 28(7), 394–400 (2001).
- Kreiss J, Ngugi E, Holmes K et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 268(4), 477–482 (1992).
- Roddy RE, Zekeng L, Ryan KA, Tamoufé U, Weir SS, Wong EL. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N. Engl. J. Med. 339(8), 504–510 (1998).
- Van Damme L, Ramjee G, Alary M et al.; COL-1492 Study Group. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360(9338), 971–977 (2002).
- Feldblum PJ, Adeiga A, Bakare R et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 3(1), e1474 (2008).
- Peterson L, Nanda K, Opoku BK et al. SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One 2(12), e1312 (2007).
- Abdool Karim SS, Richardson BA, Ramjee G et al.; HIV Prevention Trials Network (HPTN) 035 Study Team. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 25(7), 957–966 (2011).
- Lagenaur LA, Sanders-Beer BE, Brichacek B et al. Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol. 4(6), 648–657 (2011).
- Pearce-Pratt R, Phillips DM. Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1. Biol. Reprod. 54(1), 173–182 (1996).
- Saifuddin M, Doncel G, Tsai L et al. Intravaginal administration of 6% cellulose sulfate (CS) gel prevented systemic infection in rhesus macaques in a multiple dose R5/X4 SHIV vaginal challenge model. Presented at: Microbicides 2008 conference. Delhi, India, 24–27 February 2008.
- Rusconi S, Moonis M, Merrill DP et al. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob. Agents Chemother. 40(1), 234–236 (1996).
- Lewis M, Wagner W, Yalley-Ogunro J, Greenhouse J, Profy A. Efficacy of PRO 2000 gel in a macaque model for vaginal HIV transmission [Abstract A-191]. Presented at: Microbicides 2002 Conference. Antwerp, Belgium 12–15 May 2002).
- Conrad. Investigator’s brochure: sodium cellulose sulfate 6% vaginal gel. (2006).
- Núñez M, Soriano V. Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect. Dis. 5(6), 374–382 (2005).
- Scordi-Bello IA, Mosoian A, He C et al. Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob. Agents Chemother. 49(9), 3607–3615 (2005).
- Skoler-Karpoff S, Ramjee G, Ahmed K et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372(9654), 1977–1987 (2008).
- Van Damme L, Govinden R, Mirembe FM et al.; CS Study Group. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med. 359(5), 463–472 (2008).
- Doncel GF, Chandra N, Fichorova RN. Preclinical assessment of the proinflammatory potential of microbicide candidates. J. Acquir. Immune Defic. Syndr. 37(Suppl. 3), S174–S180 (2004).
- Abdool Karim Q, Abdool Karim SS, Frohlich JA et al.; CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329(5996), 1168–1174 (2010).
- Karim SS, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 378(9787), 279–281 (2011).
- Lederman MM, Veazey RS, Offord R et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306(5695), 485–487 (2004).
- Harman S, Herrera C, Armanesco N et al. L’644, a cholesterol derivatized version of the gp41 fusion peptide C34, provides superior activity in preclinical microbicide assays [abstract 19]. Presented at: 2010 International Microbicides Conference. PA, USA 56(5), 2347-2356 (2010).
- Williams BG, Abdool Karim SS, Karim QA, Gouws E. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J. Acquir. Immune Defic. Syndr. 58(2), 207–210 (2011).
- Smith AD, Tapsoba P, Peshu N, Sanders EJ, Jaffe HW. Men who have sex with men and HIV/AIDS in sub-Saharan Africa. Lancet 374(9687), 416–422 (2009).
- Voeller B. AIDS and heterosexual anal intercourse. Arch. Sex. Behav. 20(3), 233–276 (1991).
- Gross M, Holte SE, Marmor M et al. Anal sex among HIV-seronegative women at high risk of HIV exposure. JAIDS 24, 393–398 (2000).
- Halperin DT. Heterosexual anal intercourse: prevalence, cultural factors, and HIV infection and other health risks, Part I. AIDS Patient Care STDS 13(12), 717–730 (1999).
- Kalichman SC, Simbayi LC, Cain D, Jooste S. Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa. Sex. Transm. Infect. 85(6), 411–415 (2009).
- Schwandt M, Morris C, Ferguson A, Ngugi E, Moses S. Anal and dry sex in commercial sex work, and relation to risk for sexually transmitted infections and HIV in Meru, Kenya. Sex. Transm. Infect. 82(5), 392–396 (2006).
- van Oosterhout JJ, Bodasing N, Kumwenda JJ et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop. Med. Int. Health 10(5), 464–470 (2005).
- Nachega JB, Stein DM, Lehman DA et al. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res. Hum. Retroviruses 20(10), 1053–1056 (2004).
- Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN, Bangsberg DR. Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. Int. J. STD AIDS 16(1), 38–41 (2005).
- Committee on the Methodological Challenges in HIV Prevention Trials. Methodological Challenges in Biomedical HIV Prevention Trials. Lagakos SW, Gable AR (Eds). The National Academy Press, DC, USA (2008).
- Hendrix C, Minnis A, Guddera V et al. MTN-001: A Phase 2 Cross-over Study of Daily Oral and Vaginal TFV in Healthy, Sexually Active Women Results in Significantly Different Product Acceptability and Vaginal Tissue Drug Concentrations [Abstract 35LB]. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. MA, USA 27 February–2 March 2011.
- Anton PA, Cranston RD, Kashuba A et al. RMP-02/MTN-006: A Phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of Tenofovir 1% gel compared with oral Tenofovir Disoproxil Fumarate. AIDS Res. Hum. Retroviruses (2012).
- Abbas U, Glaubius R, Mubayi A, Hood G, Mellors J. Predicting the Impact of ART and PrEP with Overlapping Regimens on HIV Transmission and Drug Resistance in South Africa [abstract #98LB]. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. MA, USA 27 February–2 March 2011.
- Grant RM, Lama JR, Anderson PL et al.; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363(27), 2587–2599 (2010).
- Cassell MM, Halperin DT, Shelton JD, Stanton D. Risk compensation: the Achilles’ heel of innovations in HIV prevention? BMJ 332(7541), 605–607 (2006).
- Vissers DC, Voeten HA, Nagelkerke NJ, Habbema JD, de Vlas SJ. The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS One 3(5), e2077 (2008).
- Auvert B, Taljaard D, Rech D et al. Effect of the Orange Farm (South Africa) male circumcision roll-out (ANRS-12126) on the spread of HIV [abstract WELBC02]. Presented at: Sixth International AIDS Society Conference. Rome, Italy 19 July 2011.
- Baeten JM, Donnell D, Ndase P et al.; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367(5), 399–410 (2012).
- Thigpen MC, Kebaabetswe PM, Paxton LA et al.; TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N. Engl. J. Med. 367(5), 423–434 (2012).
- Cohen MS, Chen YQ, McCauley M et al.; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365(6), 493–505 (2011).
- Karim QA, Kharsany AB, Frohlich JA et al. Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. Int. J. Epidemiol. 40(4), 922–930 (2011).
Websites
- UNAIDS. Together we will end AIDS.Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland. www.unaids.org/en/resources/campaigns/togetherwewillendaids/ (Accessed 2 August 2012)
- National Institute of Allergy and Infectious Diseases (NIAID). Safety and Effectiveness of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate, and Emtricitabine/Tenofovir Disoproxil Fumarate Tablets in Preventing HIV in Women (2011). http://clinicaltrials.gov/ct2/show/NCT00705679 (Accessed 30 January 2012)
- Microbicide Trials Network. MTN Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women. www.mtnstopshiv.org/node/3909 (Accessed 25 November 2011)
- Microbicide Trials Network. Microbicide Trials Network Statement on Decision to Discontinue Use of Oral Tenofovir Tablets in VOICE, a Major HIV Prevention Study in Women. www.mtnstopshiv.org/node/3619 (Accessed 1 November 2011)
- International Partnership for Microbicides. Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring. http://clinicaltrials.gov/ct2/show/NCT01363037 (Accessed 30 January 2011)
- CONRAD. FACTS 001: Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Young Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection (2011). http://clinicaltrials.gov/ct2/show/NCT01386294 (Accessed 14 August 2012)
- CONRAD. CONRAD A10-113: Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel (2011). http://clinicaltrials.gov/ct2/show/NCT01369303 (Accessed 14 August 2012)
- CONRAD. CONRAD A10-114: Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use (2011). http://clinicaltrials.gov/ct2/show/NCT01421368 (Accessed 3 August 2012)
- CONRAD. MTN-007: Rectal Safety and Acceptability Study of Tenofovir 1% Gel (2010). http://clinicaltrials.gov/ct2/show/NCT01232803 (Accesed 30 January 2012)
- National Institute of Allergy and Infectious Diseases. MTN-008: Tenofovir Gel in Pregnancy and Lactation. http://clinicaltrials.gov/show/NCT01136759 (Accessed 3 August 2012)
- University of Washington. 41250-A: Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding. (2011).http://clinicaltrials.gov/ct2/show/NCT01448616 (Accessed 14 August 2012)
- CONRAD. Microbicide Safety and Acceptability in Young Men (Project Gel) (2011).http://clinicaltrials.gov/ct2/show/NCT01283360 (Accessed 30 January 2012)
- International Partnership for Microbicides. MTN-020: Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women (ASPIRE). http://clinicaltrials.gov/show/NCT01617096 (Accessed 2 August 2012)
- International Partnership for Microbicides. IPM 027: Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women.http://clinicaltrials.gov/show/NCT01539226 (Accessed 2 August 2012)
- Microbicide Trials Network. MTN-005:Safety and Adherence of a Non-medicated Intravaginal Ring.http://clinicaltrials.gov/show/NCT01268332 (Accessed 3 August 2012)
- CONRAD. CHARM-01: A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally.http://clinicaltrials.gov/ct2/show/NCT01575405 (Accessed 14 August 2012)
- CONRAD. CHARM-02: An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations. (2011).http://clinicaltrials.gov/ct2/show/NCT01575418 (Accessed 14 August 2012)
- International Partnership for Microbicides. FAME-02: Assessing the Safety of Dapivirine Gel and Film Formulations. http://clinicaltrials.gov/ct2/show/NCT01548560 (Accessed 12 August 2012)
- The HIV Vaccines and Microbicides Resource Tracking Working Group. Capitalizing on Scientific Progress: Investment in HIV Prevention R&D in 2010 (2011).www.unaids.org/en/media/unaids/contentassets/documents/pressrelease/2011/07/20110719_RTWG_Capitalizing_Scientific_Progress.pdf (Accessed 26 January 2012)
- US FDA. FDA approves first drug for reducing the risk of sexually acquired HIV infection.www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm (Accessed 19 July 2012)
- Global Advocacy for HIV prevention tables on ongoing clinical trials.http://data.avac.org/OngoingMicrobicideTrials.aspx (Accessed 14 August 2012)
- Clinical trials database. ClinicalTrials.gov (Accessed 14 August 2012)